Pulse.

a daily field guide to health research that matters

◆ Console

‹ Tue · 10 Nov 2026
Standard addition

daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma.

This trial clarifies that adding this antibody to standard pancreatic cancer drugs doesn't improve survival, helping doctors avoid ineffective treatments.

This phase III, randomized, double-blind study (daNIS-2) evaluated the efficacy and safety of NIS793, an anti-transforming growth factor-beta (TGF-β) monoclonal antibody, in combination with gemcitabine and nab-paclitaxel [standard of care (SOC)] versus placebo and SOC as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). NIS793 in combination with SOC did not improve survival outcomes in first-line mPDAC and was associated with an unfavorable benefit-risk profile.

What the study was

Study design
Randomized controlled trial
Population
This phase III, randomized, double-blind study (daNIS-2) evaluated the efficacy and safety of NIS793, an anti-transforming growth factor-beta (TGF-β) monoclonal antibody, in combination with gemcitabine and nab-paclitaxel [standard of care (SOC)] versus placebo and SOC as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Sample size
21
Category
Other
Maturity
Validated
Journal
ESMO open

Why it surfaced

Randomized controlled trial assessed from PubMed metadata and abstract text; conservatively scored 8/10 under the v1.3 rubric.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.